UA95956C2 - Набір для визначення mage-а3 - Google Patents

Набір для визначення mage-а3

Info

Publication number
UA95956C2
UA95956C2 UAA200814634A UAA200814634A UA95956C2 UA 95956 C2 UA95956 C2 UA 95956C2 UA A200814634 A UAA200814634 A UA A200814634A UA A200814634 A UAA200814634 A UA A200814634A UA 95956 C2 UA95956 C2 UA 95956C2
Authority
UA
Ukraine
Prior art keywords
mage
instruments
determination
relates
primers
Prior art date
Application number
UAA200814634A
Other languages
English (en)
Russian (ru)
Inventor
Т'єррі Кох
Олів'є Ґруселл
Денніс Салонґа
Крейґ Лоуренс Стефенс
Ґабрієль Аннмарі Бір
Original Assignee
Ґлаксосмітклайн Байолоджікалз С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ґлаксосмітклайн Байолоджікалз С.А. filed Critical Ґлаксосмітклайн Байолоджікалз С.А.
Publication of UA95956C2 publication Critical patent/UA95956C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6841—In situ hybridisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Abstract

Винахід належить до специфічних для MAGE-А3 праймерів та зондів для застосування у нових діагностичних наборах. Винахід додатково належить імунотерапевтичного лікування пацієнтів, які страждають від пухлин, що експресують MAGE-A3.
UAA200814634A 2006-06-21 2007-06-21 Набір для визначення mage-а3 UA95956C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0612342.6A GB0612342D0 (en) 2006-06-21 2006-06-21 Method
PCT/EP2007/056219 WO2007147876A2 (en) 2006-06-21 2007-06-21 Method for the detection and diagnosis of cancer involving primers and probes for the specific detection of the mage- a3 -marker

Publications (1)

Publication Number Publication Date
UA95956C2 true UA95956C2 (uk) 2011-09-26

Family

ID=36803668

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200814634A UA95956C2 (uk) 2006-06-21 2007-06-21 Набір для визначення mage-а3

Country Status (28)

Country Link
US (1) US8936919B2 (uk)
EP (1) EP2041308B1 (uk)
JP (2) JP2009540812A (uk)
KR (1) KR101455589B1 (uk)
CN (1) CN101506383B (uk)
AU (1) AU2007263019B2 (uk)
BR (1) BRPI0713599A2 (uk)
CA (1) CA2656909A1 (uk)
CO (1) CO6140072A2 (uk)
CY (1) CY1113290T1 (uk)
DK (1) DK2041308T3 (uk)
EA (1) EA016347B1 (uk)
ES (1) ES2389513T3 (uk)
GB (1) GB0612342D0 (uk)
HK (1) HK1127627A1 (uk)
HR (1) HRP20120761T1 (uk)
IL (1) IL195975A (uk)
MA (1) MA30565B1 (uk)
MX (1) MX2008016493A (uk)
MY (1) MY147511A (uk)
NO (1) NO20085290L (uk)
NZ (1) NZ573809A (uk)
PL (1) PL2041308T3 (uk)
PT (1) PT2041308E (uk)
SI (1) SI2041308T1 (uk)
UA (1) UA95956C2 (uk)
WO (1) WO2007147876A2 (uk)
ZA (1) ZA200810695B (uk)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ596545A (en) 2007-09-17 2013-05-31 Glaxosmithkline Biolog Sa Improved detection of mage-a expression
US8987423B2 (en) * 2010-07-22 2015-03-24 Glaxosmithkline Biologicals, S.A. MAGE antigen binding proteins
CN102251033B (zh) * 2011-07-05 2013-03-20 北京大学人民医院 基于mage-a3基因辅助诊断多发性骨髓瘤患者的定量检测试剂盒

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612201A (en) * 1991-05-23 1997-03-18 Ludwig Institute For Cancer Research Isolated nucleic acid molecules useful in determining expression of a tumor rejection antigen precursor
CA2141960A1 (en) * 1992-08-07 1994-02-17 Ralph T. Kubo Hla binding peptides and their uses
NZ282536A (en) * 1994-03-01 1998-07-28 Ludwig Inst Cancer Res Nucleic acid molecule useful as a primer in determining expression of a mage tumour rejections antigen precursor
US5985571A (en) 1998-02-04 1999-11-16 Ludwig Institute For Cancer Research Method for determining multiple myeloma by assaying for expression of mage genes
CZ298364B6 (cs) * 1998-02-05 2007-09-05 Smithkline Beecham Biologicals S. A. Deriváty antigenu asociovaných s nádory z MAGE rodiny a sekvence nukleových kyselin kodující tyto deriváty, jejich použití pro prípravu fúzních proteinu a prostredku pro vakcinaci
WO2000020445A2 (en) 1998-10-02 2000-04-13 Ludwig Institute For Cancer Research Tumor antigens and ctl clones isolated by a novel procedure
JP3603138B2 (ja) * 2000-02-18 2004-12-22 独立行政法人理化学研究所 細胞死抑制タンパク質
US6358679B1 (en) * 2000-08-24 2002-03-19 Pe Corporation (Ny) Methods for external controls for nucleic acid amplification
US6635425B2 (en) * 2001-01-05 2003-10-21 Molecular Staging, Inc. 5′-thio phosphate directed ligation of oligonucleotides and use in detection of single nucleotide polymorphisms
ATE446106T1 (de) 2001-11-29 2009-11-15 Dandrit Biotech As Pharmazeutische zusammensetzung zur auslösung einer immunantwort bei einem menschen oder einem tier
EP2314691A3 (en) 2002-11-14 2012-01-18 Dharmacon, Inc. Fuctional and hyperfunctional siRNA
AU2003290925A1 (en) * 2002-11-14 2004-06-15 John Wayne Cancer Institute Detection of micro metastasis of melanoma and breast cancer in paraffin-embedded tumor draining lymph nodes by multimaker quantitative rt-pcr
GB0409940D0 (en) 2004-05-04 2004-06-09 Glaxosmithkline Biolog Sa Vaccine
US20070231822A1 (en) * 2006-02-28 2007-10-04 Michael Mitas Methods for the detection and treatment of cancer

Also Published As

Publication number Publication date
BRPI0713599A2 (pt) 2012-11-06
HRP20120761T1 (hr) 2012-10-31
CO6140072A2 (es) 2010-03-19
EA016347B1 (ru) 2012-04-30
WO2007147876A3 (en) 2008-05-15
HK1127627A1 (en) 2009-10-02
JP2013046630A (ja) 2013-03-07
PL2041308T3 (pl) 2012-11-30
CY1113290T1 (el) 2016-04-13
MA30565B1 (fr) 2009-07-01
ZA200810695B (en) 2014-03-26
EP2041308B1 (en) 2012-07-11
KR101455589B1 (ko) 2014-10-28
CA2656909A1 (en) 2007-12-27
MX2008016493A (es) 2009-05-21
EA200802356A1 (ru) 2009-06-30
JP2009540812A (ja) 2009-11-26
NZ573809A (en) 2011-12-22
MY147511A (en) 2012-12-31
DK2041308T3 (da) 2012-10-08
KR20090034900A (ko) 2009-04-08
US20120040341A1 (en) 2012-02-16
AU2007263019A1 (en) 2007-12-27
ES2389513T3 (es) 2012-10-26
CN101506383B (zh) 2013-08-28
GB0612342D0 (en) 2006-08-02
CN101506383A (zh) 2009-08-12
AU2007263019B2 (en) 2012-11-08
EP2041308A2 (en) 2009-04-01
US8936919B2 (en) 2015-01-20
NO20085290L (no) 2009-01-19
JP5705191B2 (ja) 2015-04-22
IL195975A0 (en) 2009-09-01
SI2041308T1 (sl) 2012-10-30
IL195975A (en) 2012-08-30
PT2041308E (pt) 2012-10-09
WO2007147876A2 (en) 2007-12-27

Similar Documents

Publication Publication Date Title
AU2008298744A8 (en) MiRNA expression in human peripheral blood microvesicles and uses thereof
WO2010017515A3 (en) Breast cancer specific markers and methods of use
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
MX2010000405A (es) Seleccion de farmacos para terapia de cancer de pulmon usando arreglos a base de anticuerpos.
WO2011088149A3 (en) Methods for predicting response of triple-negative breast cancer to therapy
MX2013002084A (es) Biomarcadores y metodos de tratamiento.
EP3885366A3 (en) Therapeutic antibodies against ror-1 protein and methods for use of same
MX2009008347A (es) Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso.
MX2018011832A (es) Metodos y composiciones para uso en diagnostico de pacientes con cancer.
EP1934377A4 (en) METHOD AND COMPOSITIONS FOR IDENTIFYING BIOMARKERS SUITED TO THE DIAGNOSIS AND / OR TREATMENT OF BIOLOGICAL CONDITIONS
EP1784639A4 (en) PROCESS FOR PREPARING FREEZERTED BLOOD PLATES, FLUIDIZED BLOOD PLATES, COMPOSITIONS AND USE METHOD
MX2009012625A (es) Metodos para el tratamiento, diagnostico y deteccion de trastornos asociados con el fgf21.
WO2010099161A8 (en) Micrornas in never-smokers and related materials and methods
ZA200702973B (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for CDK2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
IL207637A (en) Choosing a Breast Cancer Remedy Using Antibody-Based Arrays
MX2010005244A (es) Composiciones y métodos para la terapia y el diagnóstico de influenza.
MX2010006854A (es) Biomarcadores para sensibilidad a terapia anti-receptor-1 del factor de crecimiento tipo insulina.
WO2008073899A3 (en) Prrg4-associated compositions and methods of use thereof in methods of tumor diagnosis
MX2010005057A (es) Metodos y composiciones para uso de diagnostico en pacientes de cancer.
MX2015001716A (es) Niclosamida para el tratamiento de tumores solidos.
IL202674A0 (en) Genetic variants on chr 15q24 as markers for use in diagnosis, prognosis and treatment of exfoliation syndrome and glaucoma
EP2175879A4 (en) TREATMENT OF DISEASES ASSOCIATED WITH PRION PROTEIN
MX338694B (es) Composiciones y metodos para el diagnostico y el tratamiento de tumores.
WO2012017430A3 (en) Microrna patterns for the diagnosis, prognosis and treatment of melanoma
WO2008115750A3 (en) Compositions and methods for the treatment of cancer